BRPI0507002A - conjugados veìculos de grelina - Google Patents
conjugados veìculos de grelinaInfo
- Publication number
- BRPI0507002A BRPI0507002A BRPI0507002-3A BRPI0507002A BRPI0507002A BR PI0507002 A BRPI0507002 A BR PI0507002A BR PI0507002 A BRPI0507002 A BR PI0507002A BR PI0507002 A BRPI0507002 A BR PI0507002A
- Authority
- BR
- Brazil
- Prior art keywords
- vlp
- modified
- provides
- immune responses
- producing
- Prior art date
Links
- 101800001586 Ghrelin Proteins 0.000 title abstract 2
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 title abstract 2
- 102000012004 Ghrelin Human genes 0.000 title 1
- 230000028993 immune response Effects 0.000 abstract 2
- 102400000442 Ghrelin-28 Human genes 0.000 abstract 1
- 208000015580 Increased body weight Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 230000005875 antibody response Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0325—Animal model for autoimmune diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10123—Virus like particles [VLP]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Nanotechnology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medical Informatics (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Child & Adolescent Psychology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
CONJUGADOS VEìCULOS DE GRELINA . A presente invenção aos campos da biologia melecular, virologia, imunologia e medicina. A invenção fornece uma partícula tipo vírus modificada (VLP) compreendendo uma VLP e peptídeos particulares derivados de grelina igados a ela. A invenção da mesma fornece um precessos para produzir a VLP modificada. As VLPs modificadas da invenção são úteis na produção de vacinas para o tratamento de obsidade e outra doença associada com absorção de alimento aumentada ou peso corporal aumentado e para eficientemente induzir respostas imunes, em particular, respostas de nticorpo. Além disso, as composições da invenção são particulamente úteis para eficientemente induzir respostas imunes alto-específicas dentro do contexto indicado.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53723004P | 2004-01-20 | 2004-01-20 | |
PCT/EP2005/000497 WO2005068639A2 (en) | 2004-01-20 | 2005-01-19 | Particle-induced ghrelin immune response |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0507002A true BRPI0507002A (pt) | 2007-06-05 |
Family
ID=34794443
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0507002-3A BRPI0507002A (pt) | 2004-01-20 | 2005-01-19 | conjugados veìculos de grelina |
Country Status (12)
Country | Link |
---|---|
US (1) | US20050191317A1 (pt) |
EP (1) | EP1706152A2 (pt) |
JP (1) | JP2007518762A (pt) |
KR (1) | KR20060128924A (pt) |
CN (1) | CN1905903A (pt) |
AU (1) | AU2005205181A1 (pt) |
BR (1) | BRPI0507002A (pt) |
CA (1) | CA2553594A1 (pt) |
IL (1) | IL176918A0 (pt) |
RU (1) | RU2006130006A (pt) |
WO (1) | WO2005068639A2 (pt) |
ZA (1) | ZA200604663B (pt) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2005291231B2 (en) | 2004-10-05 | 2010-12-23 | Cytos Biotechnology Ag | VLP-antigen conjugates and their uses as vaccines |
NZ554386A (en) * | 2004-10-25 | 2009-12-24 | Cytos Biotechnology Ag | Gastric inhibtory polypeptide (GIP) antigen arrays with VLPs and uses thereof |
US20110027220A1 (en) * | 2005-09-28 | 2011-02-03 | Cytos Biotechnology Ag | Interleukin-1 Conjugates and Uses Thereof |
JP5186678B2 (ja) * | 2005-10-13 | 2013-04-17 | 財団法人ヒューマンサイエンス振興財団 | 経皮抗原投与のための抗原キット |
MX2009001133A (es) * | 2006-08-01 | 2009-02-11 | Scripps Research Inst | Vacunas y metodos para controlar adiposidad. |
HUE051430T2 (hu) * | 2009-07-10 | 2021-03-01 | Ablynx Nv | Eljárás variábilis domének elõállítására |
WO2011053821A1 (en) | 2009-10-30 | 2011-05-05 | Tranzyme Pharma, Inc. | Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same |
BR112014013035A2 (pt) | 2011-12-22 | 2018-10-09 | Hoffmann La Roche | métodos de seleção de células, conjuntos de expressão bicistrônica, células eucarióticas, vetores lentivirais, uso de vetor lentiviral, bibliotecas de ventores lentivirais e de células eucarióticas, métodos de seleção de células, fluxos de trabalho e uso de célula |
WO2013119800A1 (en) | 2012-02-07 | 2013-08-15 | Massachusetts Institute Of Technology | Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness |
US9724396B2 (en) | 2013-03-15 | 2017-08-08 | Massachusetts Institute Of Technology | Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness |
WO2015193143A1 (en) * | 2014-06-18 | 2015-12-23 | Morphosys Ag | Fusion proteins and uses thereof |
EA035378B1 (ru) | 2015-01-15 | 2020-06-04 | Юниверсити Оф Копенгаген | Вирусоподобная частица с эффективным экспонированием эпитопов |
WO2016138099A1 (en) | 2015-02-24 | 2016-09-01 | Massachusetts Institute Of Technology | Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness |
ES2854726T3 (es) | 2015-10-30 | 2021-09-22 | The Univ Of Copenhagen | Partícula similar a virus con presentación eficiente de epítopos |
JPWO2017170494A1 (ja) * | 2016-03-29 | 2019-02-14 | 国立大学法人 東京大学 | 抗肥満ワクチン |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4722840A (en) * | 1984-09-12 | 1988-02-02 | Chiron Corporation | Hybrid particle immunogens |
US5374426A (en) * | 1986-09-03 | 1994-12-20 | University Of Saskatchewan | Rotavirus nucleocapsid protein VP6 in vaccine compositions |
US5143726A (en) * | 1986-12-09 | 1992-09-01 | The Scripps Research Institute | T cell epitopes of the hepatitis B virus nucleocapsid protein |
US4918166A (en) * | 1987-04-10 | 1990-04-17 | Oxford Gene Systems Limited | Particulate hybrid HIV antigens |
US5057540A (en) * | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
AU633698B2 (en) * | 1990-01-12 | 1993-02-04 | Amgen Fremont Inc. | Generation of xenogeneic antibodies |
US5334394A (en) * | 1990-06-22 | 1994-08-02 | The Regents Of The University Of California | Human immunodeficiency virus decoy |
SE9003978D0 (sv) * | 1990-12-13 | 1990-12-13 | Henrik Garoff | Dna expressionssystem baserade paa ett virus replikon |
GB9114003D0 (en) * | 1991-06-28 | 1991-08-14 | Mastico Robert A | Chimaeric protein |
US6004763A (en) * | 1992-09-11 | 1999-12-21 | Institut Pasteur | Antigen-carrying microparticles and their use in the induction of humoral or cellular responses |
FR2695563B1 (fr) * | 1992-09-11 | 1994-12-02 | Pasteur Institut | Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires. |
US5928647A (en) * | 1993-01-11 | 1999-07-27 | Dana-Farber Cancer Institute | Inducing cytotoxic T lymphocyte responses |
AU6172194A (en) * | 1993-02-08 | 1994-08-29 | Paravax, Inc. | Defective sindbis virus vectors that express (toxoplasma gondii) p30 antigens |
US6015686A (en) * | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
US5792462A (en) * | 1995-05-23 | 1998-08-11 | University Of North Carolina At Chapel Hill | Alphavirus RNA replicon systems |
US5770380A (en) * | 1996-09-13 | 1998-06-23 | University Of Pittsburgh | Synthetic antibody mimics--multiple peptide loops attached to a molecular scaffold |
US6380158B1 (en) * | 1997-03-24 | 2002-04-30 | Zymogenetics, Inc. | Motilin homologs |
US6627729B1 (en) * | 1997-03-24 | 2003-09-30 | Zymogenetics, Inc. | TML peptides |
US6291653B1 (en) * | 1997-03-24 | 2001-09-18 | Zymogenetics, Inc. | Antibodies to motilin homologs |
US6054312A (en) * | 1997-08-29 | 2000-04-25 | Selective Genetics, Inc. | Receptor-mediated gene delivery using bacteriophage vectors |
CA2320488C (en) * | 1998-02-12 | 2007-03-06 | Immune Complex, Corporation | Strategically modified hepatitis b core proteins and their derivatives |
WO2000023955A1 (en) * | 1998-10-21 | 2000-04-27 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Virus-like particles for the induction of autoantibodies |
US6380364B1 (en) * | 1998-11-23 | 2002-04-30 | Loyola University Of Chicago | Chimeric biotin-binding papillomavirus protein |
ATE412434T1 (de) * | 1998-11-30 | 2008-11-15 | Cytos Biotechnology Ag | Molekulare anordnung von allergenen, verfahren zur deren herstellung und deren verwendung |
TR200102423T2 (tr) * | 1998-12-04 | 2002-02-21 | Biogen, Inc. | Peptid ligandları yoluyla bağlı birden fazla imünojenik bileşeni olan HBV çekirdek antijeni parçacıkları |
US6420521B1 (en) * | 1999-06-30 | 2002-07-16 | Zymogenetics, Inc. | Short gastrointestinal peptides |
CN100506844C (zh) * | 1999-07-23 | 2009-07-01 | 寒川贤治 | 新的肽 |
US6558695B2 (en) * | 1999-12-16 | 2003-05-06 | Dermatrends, Inc. | Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers |
CA2407897A1 (en) * | 2000-05-05 | 2001-11-15 | Cytos Biotechnology Ag | Molecular antigen arrays and vaccines |
JP2004514651A (ja) * | 2000-05-30 | 2004-05-20 | メルク エンド カムパニー インコーポレーテッド | グレリン類似体 |
US7094409B2 (en) * | 2001-01-19 | 2006-08-22 | Cytos Biotechnology Ag | Antigen arrays for treatment of allergic eosinophilic diseases |
US7320793B2 (en) * | 2001-01-19 | 2008-01-22 | Cytos Biotechnology Ag | Molecular antigen array |
US7128911B2 (en) * | 2001-01-19 | 2006-10-31 | Cytos Biotechnology Ag | Antigen arrays for treatment of bone disease |
CN1599623B (zh) * | 2001-09-14 | 2011-05-11 | 赛托斯生物技术公司 | 免疫刺激物向病毒样颗粒内的包装:制备方法与用途 |
CN1558774B (zh) * | 2001-10-05 | 2012-03-14 | 赛托斯生物技术公司 | 血管紧张肽-载体偶联物及其用途 |
DK1441764T3 (da) * | 2001-11-07 | 2009-01-26 | Cytos Biotechnology Ag | Antigen-Arrays der omfatter RANKL til behandling af knoglesygdom |
NZ537001A (en) * | 2002-07-19 | 2007-04-27 | Cytos Biotechnology Ag | A composition comprising a virus-like particle and at least ghrelin or a ghrelin-derived peptide bound thereto |
EP1633397A2 (en) * | 2003-06-04 | 2006-03-15 | Eli Lilly And Company | Anti-ghrelin fab antibodies |
-
2005
- 2005-01-19 RU RU2006130006/13A patent/RU2006130006A/ru not_active Application Discontinuation
- 2005-01-19 US US11/037,396 patent/US20050191317A1/en not_active Abandoned
- 2005-01-19 BR BRPI0507002-3A patent/BRPI0507002A/pt not_active IP Right Cessation
- 2005-01-19 CN CNA2005800017590A patent/CN1905903A/zh active Pending
- 2005-01-19 JP JP2006550027A patent/JP2007518762A/ja not_active Withdrawn
- 2005-01-19 EP EP05701048A patent/EP1706152A2/en not_active Withdrawn
- 2005-01-19 ZA ZA200604663A patent/ZA200604663B/en unknown
- 2005-01-19 WO PCT/EP2005/000497 patent/WO2005068639A2/en active Application Filing
- 2005-01-19 CA CA002553594A patent/CA2553594A1/en not_active Abandoned
- 2005-01-19 AU AU2005205181A patent/AU2005205181A1/en not_active Abandoned
- 2005-01-19 KR KR1020067014632A patent/KR20060128924A/ko not_active Application Discontinuation
-
2006
- 2006-07-18 IL IL176918A patent/IL176918A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20060128924A (ko) | 2006-12-14 |
JP2007518762A (ja) | 2007-07-12 |
EP1706152A2 (en) | 2006-10-04 |
RU2006130006A (ru) | 2008-02-27 |
AU2005205181A1 (en) | 2005-07-28 |
CN1905903A (zh) | 2007-01-31 |
US20050191317A1 (en) | 2005-09-01 |
WO2005068639A2 (en) | 2005-07-28 |
CA2553594A1 (en) | 2005-07-28 |
ZA200604663B (en) | 2008-02-27 |
IL176918A0 (en) | 2006-12-10 |
WO2005068639A3 (en) | 2006-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0507002A (pt) | conjugados veìculos de grelina | |
BRPI0511751A (pt) | usos médicos de conjugados veìculos de peptìdeos de tnf não-humano | |
CY1123978T1 (el) | Σταθερα και διαλυτα αντισωματα που αναστελλουν ton tnf | |
BRPI0516775A (pt) | ensaios de polipeptìdeo de antìgeno de inibidor gástrico (gip) e seus usos | |
BRPI0707779B8 (pt) | antígeno isolado, composição de vacina e método para produção de uma proteína antígeno | |
DOP2014000083A (es) | Inmunoenlazadores dirigidos contra el tnf | |
BRPI0518761A2 (pt) | fusço de droga, conjugado de droga, Ácido nucleico recombinante, construÇço de Ácido nucleico, cÉlula hospedeira, mÉtodo para produzir uma fusço de droga, composiÇço farmacÊutica, droga, mÉtodo de tratamento e/ou prevenÇço de uma condiÇço em um paciente, mÉtodo de retardo ou prevenÇço de progressço de doenÇa, e, mÉtodo para diminuir a absorÇço de alimentos por um paciente | |
CY1119941T1 (el) | Σταθερα και διαλυτα αντισωματα | |
NO20083793L (no) | Antistoffer mot amyloid-beta peptid | |
BRPI0408623A (pt) | conjugados de partìcula semelhante ao vìrus análogo de peptìdeo de melan-a | |
DE60329106D1 (de) | Ghrelin-träger-konjugate | |
WO2006097530A3 (en) | Cat allergen fusion proteins and uses thereof | |
BR112014017384A2 (pt) | ácido nucleico que compreende ou codifica para uma estrutura em haste laçada de histona e uma sequência poli (a) ou um sinal de poliadenilação para aumentar a expressão de um antigênio de tumor codificado | |
BR112015021921A2 (pt) | Anticorpos biespecíficos tetravalente | |
GT201200271A (es) | Proteínas que se unen al tnf-a | |
BR112014006376A2 (pt) | terapia baseada em proteínas e diagnóstico de patologia mediada por tau em doença de alzheimer | |
BRPI0610093A2 (pt) | composiÇço farmacÊutica, e, mÉtodo para prevenir ou tratar uma doenÇa associada com os depàsitos de amilàides de alfa-beta no cÉrebro de um paciente | |
BRPI0519026A2 (pt) | arranjos de antÍgeno de il-15 e usos dos mesmos | |
BR112014020019A2 (pt) | vetores poxvirais recombinantes expressando tanto proteínas da raiva e ox40 e vacinas feitos a partir destes | |
BR112014016361A2 (pt) | ácido nucleico que compreende ou codifica uma alça peduncular de histona e uma sequência poli(a) ou um sinal de poliadenilação para aumentar a expressão de um antígeno patogênico codificado | |
WO2009035494A3 (en) | Methods for producing anti-glycan antibodies, vaccines and methods for treating cancer or infectious disease | |
BRPI1014718A2 (pt) | polipeptídeo do papiloma vírus humano, capsômero, partícula tipo vírus, composição imunogência, molécula de ácido nucléico, e, métodos para produzir o polipeptídeo, e, para preparar uma composição imunogênica | |
BR112015032713A2 (pt) | composto; composição terapêutica; composição farmacêutica; método para tratar o câncer em um paciente em necessidade; e método para induzir anticorpos em um animal ou um humano para a finalidade de criar anticorpos monoclonais para usos terapêuticos ou diagnósticos | |
WO2006027300A3 (en) | Carrier conjugates of gnrh-peptides | |
BR112014017242A8 (pt) | vlps contendo hpv l2 imunogênico e composições e métodos relacionados |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A E 6A ANUIDADES |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2099 DE 29/03/2011. |
|
B15K | Others concerning applications: alteration of classification |
Ipc: B82Y 5/00 (2011.01), A61K 39/00 (2006.01), A61K 47 |